Biomedical Applications of Nanoscale Devices

TABLE OF CONTENTS

INTRODUCTION

• REASON FOR STUDY AND ITS IMPORTANCE
• INTENDED AUDIENCE OF THIS REPORT
• SCOPE AND CONTENT OF THE REPORT
• METHODOLOGY AND INFORMATION SOURCES
• ANALYST'S CREDENTIALS
• RELEVANT BCC REPORTS
• MONTHLY NEWSLETTERS
• BCC ON-LINE SERVICES

SUMMARY

• Summary Table:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Summary Figure:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)

OVERVIEW

• COVERAGE DEFINED
  • COVERAGE DEFINED (CONTINUED)
• NANOMEDICINE
• Table 1 NANOMEDICINE TAXONOMY
  • NANOTECHNOLOGY
    • Nanotechnology (Continued)
• Table 2 SIZES OF NANOSCALE OBJECTS-NATURE VS. MANUFACTURE
  • BIOTECHNOLOGY VS. NANOTECHNOLOGY
    • Biotechnology vs. Nanotechnology (Continued)
    • Biotechnology vs. Nanotechnology (Continued)
  • LITHOGRAPHY
  • OBSTACLES TO THE DEVELOPMENT OF NANOTECHNOLOGY
    • FEAR OF NANO
      • Fear of Nano (Continued)
      • Fear of Nano (Continued)
    • SHORTAGE OF EXPERTS
    • HYPE
      • HYPE (Continued)

REGULATION

• REGULATION OF DRUGS AND BIOMEDICAL DEVICES
  • REGULATION IN THE U.S.
    • Devices
      • Devices (Continued)
• Table 3 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN MEDICAL DEVICE REGULATION
  • Devices (Continued)
  • Drugs and Biologicals
• Table 4 STAGES OF DRUG CANDIDATE REVIEW
  • Diagnostics
  • Orphan Product Status
  • INTERNATIONAL ISSUES
    • ISO 9000
  • GENERAL REGULATION OF NANOTECHNOLOGY
    • GENERAL REGULATION OF NANOTECHNOLOGY (CONTINUED)

TYPICAL NANOSCALE DEVICES

• CONCEPTS AND REALITIES
  • THE ASSEMBLER
    • The Assembler (Continued)
    • The Assembler (Continued)
  • DENDRIMERS
  • ARTIFICIAL ANTIBODIES-APTAMERS
  • LIQUID CRYSTAL
  • DESIGNER MACROMOLECULES
  • PROTEINS WITH NON-NATURAL AMINO ACIDS
  • SELF-ASSEMBLING NANOSTRUCTURES
  • PORPHYRIN POLYMERS
  • BUILDING WITH VIRUSES
  • MODIFIED SPIDER SILK
  • RIBOZYMES
  • MEMS/NEMS
    • Mems/Nems (Continued)
  • MOLECULAR MOTORS
  • SPECIAL PURPOSE MOTORS
  • NANOTUBES
  • FLUORESCENCE
  • NANOTUBE THERMOMETER
    • Spiral-Shaped Nanotubes from Organic Chemicals
    • Thin Films

APPLICATIONS FOR NANOSCALE DEVICES

• Table 5 NANOSCALE DEVICES AND APLICATIONS
• Table 6 BIOMEDICAL MARKETS POTENTIALLY ADDRESSABLE BY NANODEVICES, 2002
• Table 7 GLOBAL PROJECTED SALES OF BIOMEDICAL NANOSCALE DEVICES BY APPLICATION, THROUGH 2007 ($ MILLIONS)
  • ARTIFICIAL CELLS
    • ARTIFICIAL CELLS (CONTINUED)
    • ARTIFICIAL CELLS (CONTINUED)
    • MARKET OPPORTUNITY FOR ARTIFICIAL CELLS
• Table 8 GLOBAL BIOMEDICAL MARKET REVENUES FROM ARTIFICIAL CELLS, THROUGH 2007 ($ MILLIONS)
  • ARTIFICIAL ORGAN IMPLANTS
    • AUDITORY BRAINSTEM IMPLANT
    • ARTIFICIAL RETINA
      • Artificial Retina (Continued)
    • ARTIFICIAL PANCREAS
    • MARKET OPPORTUNITY FOR ARTIFICIAL ORGANS
• Table 9 GLOBAL REVENUES DERIVED FROM NANOSCALE ARTIFICIAL ORGANS, THROUGH 2007 ($ MILLIONS)
  • BIOTAGS
• Table 10 PROPERTIES OF SELECTED BIOTAGS
  • DIAGNOSTICS AND ANALYTICS
• Table 11 MEDICAL ANALYSIS AT DIFFERENT LEVELS OF RESOLUTION
• Table 12 COMMONLY USED TOOLS FOR BIOMOLECULAR ANALYSIS
  • BIOSENSORS
• Table 13 BIOSENSOR COMPONENTS
• Table 13 (CONTINUED)
  • Biosensors (Continued)
• Table 14 BIOASSAYS EMPLOYING NANSCALE COMPONENTS
  • RESONANCE LIGHT SCATTERING
  • SURFACE PLASMON RESONANCE
  • THIN FILM PLANAR WAVE-GUIDE TECHNOLOGY
  • OLFACTORY RECEPTOR SENSORS-THE ARTIFICIAL NOSE
    • Olfactory Receptor Sensors-The Artificial�EContinued)
  • CANTILEVERS
  • NANOPARTICLE-BASED ASSAYS
    • Nanoparticle-Based Assays (Continued)
    • Nanoparticle-Based Assays (Continued)
  • MAGNETIC RESISTANCE ASSAYS
  • MEMBRANES
  • PIEZOELECTRIC ACOUSTIC ASSAYS
  • MICRO/NANO TRANSPONDERS
  • LIVING CELL BIOSENSORS
  • NANOCRYSTAL ANTENNA TRANSDUCER
  • PROTEIN BENDING BIOSWITCHES
  • ELECTRICAL FLOW THROUGH DNA
  • POROUS GLASS SENSORS
  • MICRO- AND NANOFLUIDICS
    • Micro- and Nanofluidics (Continued)
  • QUANTUM DOTS
  • NANOARRAYS
  • MARKET OPPORTUNITY FOR DIAGNOSTICS AND ANALYTICS
    • Market Opportunity forAnalytics�EContinued)
• Table 15 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Figure 1 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
  • DRUGS AND DRUG DELIVERY
• Table 16 NANOSCALE DEVICES USED FOR DRUG DELIVERY
• Table 16 (CONTINUED)
  • FULLERENES
  • "HOMING" QUANTUM DOTS
  • NANOCLINIC
  • MOLECULAR TRANSPORT
  • IMPLANTABLE CHIPS
  • NANOPARTICLES
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
  • INTRACELLULAR DELIVERY REGULATION
  • LIPOSOMES AND OTHER VESICLES
    • Liposomes and Other Vesicles (Continued)
    • Liposomes and Other Vesicles (Continued)
  • NANOEMULSIONS
  • NANOSHELLS
  • PUMPS
  • ANTIVIRAL GEL
  • MARKET OPPORTUNITY FOR DRUGS AND DRUG DELIVERY
• Table 17 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, THROUGH 2007 ($ MILLIONS)
• Figure 2 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, 2002-2007 ($ MILLIONS)
  • IMAGING AND NANOTOOLS
    • ATOMIC FORCE AND SCANNING TUNNELING MICROSCOPES
      • Atomic Force and Scanning Tunneling�EContinued)
    • ANGSTROVISION
    • NANOMANIPULATORS
    • X-RAY TUBES
      • X-Ray Tubes (Continued)
    • IMAGING FROM INSIDE THE BODY
    • CONTRAST AGENTS
      • Contrast Agents (Continued)
    • MARKET OPPORTUNITIES FOR IMAGING AND NANOTOOLS
      • AFM, STM and Accessories
      • X-ray Cathodes
      • Contrast Agents
• Table 18 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, THROUGH 2007 ($ MILLIONS)
• Figure 3 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, 2002-2007 ($ MILLIONS)
  • MOLECULAR MODELING
    • MOLECULAR MODELING (CONTINUED)
• Table 19 PROPERTIES SUSCEPTIBLE TO MODELING
  • MARKET OPPORTUNITY FOR MOLECULAR MODELING SOFTWARE
• Table 20 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, THROUGH 2007 ($ MILLIONS)
• Figure 4 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, 2001-2007 ($ MILLIONS)
  • BRAIN/MACHINE INTERFACE
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • WIRELESS INTEGRATED MICROSYSTEMS (WIMS)
    • IMPLANT SURFACE
    • COMMERCIAL OPPORTUNITIES FOR BRAIN/MACHINE INTERFACE
• Table 21 GLOBAL REVENUES DERIVED FROM THE BRAIN MACHINE INTERFACE, THROUGH 2007 ($ MILLIONS)

PRODUCTS-NANOSCALE DEVICES AND TOOLS

• ARTIFICIAL ORGANS
  • ARTIFICIAL RETINA-OPTOBIONICS ASR MICROCHIP
  • BIOTAGS
    • Evident Technologies-Evidots (Nanocrystals)
    • Nanoprobe-Nanogold Labels
    • Quantum Dot Corp.-Streptavidin Conjugated Qdots
• DIAGNOSTICS AND ANALYTICS
  • AMBRI SENSIDX SYSTEM
  • BIACORE SYSTEMS (SURFACE PLASMON RESONANCE (SPR))
  • BIOFORCE NANOSCIENCES-NANOPRO
  • EVIDENT TECHNOLOGIES-EVIARRAY (BIOTHREAT DETECTION SYSTEM)
  • GENICON SCIENCE-MICROARRAY TOOLKITS
  • NANOSPHERE-NANOPARTICLE PROBE ASSAYS
  • PHARMASEQ-TSUNAMI II FLOW READER AND ASSAY KITS
  • ZEPTOSEN AG-SENSICHIP PRODUCTS
  • ZEPTOMARK HIGH PERFORMANCE PROTEIN MICROARRAYS
  • DIP-PEN NANOLITHOGRAPHY-NANOINK'S NSCRIPTOR
• DRUGS AND DRUG DELIVERY SYSTEMS
  • ABI-007
  • ACTICOAT (NUCRYST PHARMACEUTICALS)
  • NANOGATE
  • P80DOX-NP
  • RENAZORB
• FLUIDICS
  • FLUIDIGM TOPAZ PROTEIN CRYSTALIZATION SYSTEM
• NANOTOOLS
  • 3RD-TECH NANOMANIPULATOR
  • ASYLUM RESEARCH-NANOFLOW FLUID CONTROLLER
  • ASYLUM RESEARCH-MOLECULAR FORCE PROBE
  • THE BIORYX 200 SYSTEM
  • HYSITRON-TRIBOINDENTER
    • Hysitron-Triboindenter (Continued)
  • JPK INSTRUMENTS NANOWIZARD ATOMIC FORCE MICROSCOPE
  • MOLECULAR IMAGING-PICO-SPM II SCANNING MICROSCOPE
  • VEECO (DIGITAL IMAGING)-BIOSCOPE ATOMIC FORCE MICROSCOPE
  • VEECO-DIMENSION 3100 SCANNING PROBE MICROSCOPE
  • VEECO-MULTIMODE PICOFORCE SYSTEM
  • VEECO-SCENTRIS CANTILEVER SENSOR RESEARCH TOOL
  • ZYVEX-S100 NANOMANIPULATOR
• MOLECULAR MODELING SOFTWARE
  • ACCELRYS-MATERIALS STUDIO 2.2
  • TRIPOS-MOLECULAR MODELING SOFTWARE
    • Tripos-Molecular Modeling Software (Continued)

FUTURE PROSPECTS

• CONVERGING DISCIPLINES
  • CONVERGING DISCIPLINES (CONTINUED)
  • CONVERGING DISCIPLINES (CONTINUED)
  • CONVERGING DISCIPLINES (CONTINUED)
• STATE OF THE INDUSTRY
• Table 22 SKILLS AND WORK STYLES OF ACADEMICS VS. INDUSTRY
  • DIVISIONS OF LABOR
    • IMAGING AND NANOTOOLS
• Table 23 COMPANIES INVOLVED IN IMAGING AND NANOTOOLS
• Table 23 (CONTINUED)
  • DRUGS AND DRUG DELIVERY
• Table 24 DRUGS OR DRUG DELIVERY
• Table 24 (CONTINUED)
  • DIAGNOSTICS AND ANALYTICS
• Table 25 COMPANIES THAT MAKE MOLECULAR DIAGNOSTICS OR ANALYTICS
• Table 25 (CONTINUED)
  • MOLECULAR MODELING
• Table 26 COMPANIES SELLING SOFTWARE FOR MODELING MOLECULES OR NANOSCALE MATERIALS
  • GENERIC NANOMATERIALS FOR MEDICAL DEVICES
• Table 27 COMPANIES THAT MAKE NANOMATERIALS FOR MEDICAL DEVICES
  • GENERAL NANOBIOTECHNOLOGY
• Table 28 GENERAL NANOBIOTECHNOLOGY (UNCLASSIFIABLE) COMPANIES
• Table 29 DISTRIBUTION OF PUBLIC VS PRIVATE NANOBIOTECH COMPANIES
• Figure 5 DISTRIBUTION NANOBIOTECH COMPANIES BY TECHNOLOGY CATEGORY (%)
  • MARKET LEADERS
• Table 30 REVENUES AND MARKET SHARE OF LEADING BIOMEDICAL NANOSCALE DEVICE COMPANIES, THROUGH 2007

COMPANY PROFILES

• 3RD TECH, INC.
  • OFFICERS:
• 454 CORP.
  • OFFICERS:
• ACCELRYS INC.
  • OFFICERS:
• ADVECTUS INTERNATIONAL, LLC
  • OFFICERS:
• AGAVE BIOSYSTEMS
  • OFFICERS:
• AKUBIO
  • OFFICERS:
• ALLEGRO TECHNOLOGIES, LTD.
  • OFFICERS:
• ALTAIR NANOTECHNOLOGIES
  • OFFICERS:
• AMBRI, LTD.
  • OFFICERS
• AMERICAN PHARMACEUTICAL PARTNERS
  • OFFICERS
• ANOSYS, INC.
  • OFFICERS:
• ARDESTA
  • OFFICERS:
• APEX NANOTECHNOLOGIES
  • OFFICERS:
• APPLIED NANOTECH, INC
  • OFFICERS: (S.I. DIAMOND)
• APPLIED NANOTECHNOLOGIES, INC.
  • OFFICERS:
• ARGONIDE NANOMATERIALS CORP
  • OFFICERS:
• ARRYX
  • OFFICERS:
• ASYLUM RESEARCH, INC.
  • OFFICERS:
• BAXTER HEALTHCARE
  • OFFICERS:
• BIACORE
  • OFFICERS:
• BIODELIVERY SCIENCES INTERNATIONAL
  • OFFICERS:
• BIOELECTROSPEC
  • OFFICERS:
• BIOFORCE NANOSCIENCES
  • OFFICERS:
• BIOPHAN TECHNOLOGIES, INC.
  • OFFICERS:
• BIOSANTE PHARMACEUTICALS
  • OFFICERS:
• BIOTROVE, INC.
  • OFFICERS:
• CALIBRANT BIOSYSTEMS
  • OFFICERS:
• CANTION A/S
  • OFFICERS:
• CAPSULUTION NANOSCIENCE AG
  • OFFICERS:
• CHIPRX, INC.
  • OFFICERS:
• C SIXTY, INC.
  • OFFICERS:
• DENDRITIC NANOTECHNOLOGIES
  • OFFICERS:
• EAGLE RESEARCH AND DEVELOPMENT
  • OFFICERS:
• EIFFEL TECHNOLOGIES LMT
  • OFFICERS:
• ELAN
  • OFFICERS:
• ENGENEOS
  • OFFICERS:
• E-SPIN
  • OFFICERS:
• EVIDENT TECHNOLOGIES
  • OFFICERS:
• FLUIDIGM
  • OFFICERS:
• GENEFLUIDICS
  • OFFICERS:
• GENERAL NANOTECHNOLOGY, INC.
  • OFFICERS:
• GENICON SCIENCES
  • OFFICERS:
• GENEOHM SCIENCES, INC.
  • OFFICERS:
• HANDYLAB
  • OFFICERS:
• HEMOTEQ NANOCOATING DESIGN
  • OFFICERS:
• HYBRID PLASTICS
  • OFFICERS:
• HYSITRON
  • OFFICERS:
• IATROQUEST
  • OFFICERS:
• IMEDD INC.
  • OFFICERS:
• INTEL
  • OFFICERS:
• INTERNATIONAL BUSINESS MACHINES (IBM)
  • OFFICERS:
• INSERT THERAPEUTICS, INC.
  • OFFICERS:
• INTEGRATED NANOSYSTEMS, INC.
  • OFFICERS:
• ISSYS (INTEGRATED SENSING SYSTEMS)
  • OFFICERS:
• JPK INSTRUMENTS AG
  • OFFICERS:
• KEREOS
  • OFFICERS:
• KLEINDIEK NANOTECHNIK
  • OFFICERS:
• KLOCKE NANOTECHNIK
  • OFFICERS:
• LIFESENSORS, INC.
  • OFFICERS:
• LIPLASOME PHARMA A/S
  • OFFICERS:
• LUNA NANOMATERIALS
• MAXWELL SENSORS
  • OFFICERS:
• MEDITECH FEFER, INC.
  • OFFICERS:
• MEMGEN, INC.
  • OFFICERS:
• MICROCHIPS, INC.
  • OFFICERS:
• MICROMOD PARTIKELTECHNOLOGIE GMBH
• MOLECULAR IMAGING CORP.
• MOLECULAR NANOSYSTEMS
  • OFFICERS:
• NANOBACLABS, INC.
  • OFFICERS:
• NANOBIO CORP.
  • OFFICERS:
• NANOBIODYNAMICS
  • OFFICERS:
• NANOBIOMAGNETICS, INC.
  • OFFICERS:
• NANOCARRIER
  • OFFICERS:
• NANOFRAMES
  • OFFICERS:
• NANOGEN
  • OFFICERS:
• NANOINK, INC.
  • OFFICERS
• NANOLYTICS
  • OFFICERS:
• NANOMED PHARMACEUTICALS
  • OFFICERS:
• NANOMEDX GMBH
  • OFFICERS:
• NANOPHARM AG
  • OFFICERS:
• NANOPLEX TECHNOLOGIES, INC.
  • OFFICERS:
• NANOPROBES, INC.
  • OFFICERS:
• NANOSENSORS GMBH
  • OFFICERS:
• NANOSPECTRA BIOSCIENCES
  • OFFICERS:
• NANOSPHERE, INC.
  • OFFICERS:
• NANOSYS INC.
  • OFFICERS:
• NANOTYPE GMBH
  • OFFICERS:
• NASCACELL GMBH
  • OFFICERS:
• NOMADICS LIFE SCIENCES
  • OFFICERS: (NOMADICS, INC.)
• NOVAVAX, INC
  • OFFICERS:
• NTERA LTD
  • OFFICERS:
• NUCRYST PHARMACEUTICALS
  • OFFICERS:
• OPTOBIONICS CORP.
  • OFFICERS:
• OXFORD BIOSENSORS LTD.
  • OFFICERS:
• PHARMASEQ
  • OFFICERS:
• PICOLITER
  • OFFICERS:
• PLATYPUS TECHNOLOGIES
  • OFFICERS:
• PROTIVERIS TECHNOLOGIES
  • OFFICERS:
• PSIVIDA
  • OFFICERS:
• QUANTUM DOT
  • OFFICERS:
• QUANTUM LOGIC
  • OFFICERS:
• QUANTUM PRECISION INSTRUMENTS PTY. LTD.
  • OFFICERS:
• SKYE PHARMACEUTICALS, INC
  • OFFICERS:
• SOLEXA LTD
  • OFFICERS:
• SPHERICS
  • OFFICERS:
• STARPHARMA GROUP
  • OFFICERS:
• SUNYX SURFACE TECHNOLOGIES GMBH
  • OFFICERS:
• SURROMED
  • OFFICERS:
• TARGESOME
  • OFFICERS:
• TDA RESEARCH
  • OFFICERS:
• THALES NANOTECHNOLOGY
  • OFFICERS:
• TRITON BIOSYSTEMS
  • OFFICERS:
• U.S. GENOMICS
  • OFFICERS:
• VEECO INSTRUMENTS INC
  • OFFICERS:
• VIALOGY CORP.
  • OFFICERS:
• XETAL BIOTECHNIKS, LTD
  • OFFICERS:
• ZEPTOSENS AG
  • OFFICERS:
• ZYVEX
  • OFFICERS:

APPENDIX

• ACRONYMS

LIST OF TABLES

• Summary Table:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Table 1 NANOMEDICINE TAXONOMY
• Table 2 SIZES OF NANOSCALE OBJECTS-NATURE VS. MANUFACTURE
• Table 3 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN MEDICAL DEVICE REGULATION
• Table 4 STAGES OF DRUG CANDIDATE REVIEW
• Table 5 NANOSCALE DEVICES AND APLICATIONS
• Table 6 BIOMEDICAL MARKETS POTENTIALLY ADDRESSABLE BY NANODEVICES, 2002
• Table 7 GLOBAL PROJECTED SALES OF BIOMEDICAL NANOSCALE DEVICES BY APPLICATION, THROUGH 2007 ($ MILLIONS)
• Table 8 GLOBAL BIOMEDICAL MARKET REVENUES FROM ARTIFICIAL CELLS, THROUGH 2007 ($ MILLIONS)
• Table 9 GLOBAL REVENUES DERIVED FROM NANOSCALE ARTIFICIAL ORGANS, THROUGH 2007 ($ MILLIONS)
• Table 10 PROPERTIES OF SELECTED BIOTAGS
• Table 11 MEDICAL ANALYSIS AT DIFFERENT LEVELS OF RESOLUTION
• Table 12 COMMONLY USED TOOLS FOR BIOMOLECULAR ANALYSIS
• Table 13 BIOSENSOR COMPONENTS
• Table 14 BIOASSAYS EMPLOYING NANSCALE COMPONENTS
• Table 15 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Table 16 NANOSCALE DEVICES USED FOR DRUG DELIVERY
• Table 17 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, THROUGH 2007 ($ MILLIONS)
• Table 18 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, THROUGH 2007 ($ MILLIONS)
• Table 19 PROPERTIES SUSCEPTIBLE TO MODELING
• Table 20 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, THROUGH 2007 ($ MILLIONS)
• Table 21 GLOBAL REVENUES DERIVED FROM THE BRAIN MACHINE INTERFACE, THROUGH 2007 ($ MILLIONS)
• Table 22 SKILLS AND WORK STYLES OF ACADEMICS VS. INDUSTRY
• Table 23 COMPANIES INVOLVED IN IMAGING AND NANOTOOLS
• Table 24 DRUGS OR DRUG DELIVERY
• Table 25 COMPANIES THAT MAKE MOLECULAR DIAGNOSTICS OR ANALYTICS
• Table 26 COMPANIES SELLING SOFTWARE FOR MODELING MOLECULES OR NANOSCALE MATERIALS
• Table 27 COMPANIES THAT MAKE NANOMATERIALS FOR MEDICAL DEVICES
• Table 28 GENERAL NANOBIOTECHNOLOGY (UNCLASSIFIABLE) COMPANIES
• Table 29 DISTRIBUTION OF PUBLIC VS PRIVATE NANOBIOTECH COMPANIES
• Table 30 REVENUES AND MARKET SHARE OF LEADING BIOMEDICAL NANOSCALE DEVICE COMPANIES, THROUGH 2007  

LIST OF FIGURES

• Summary Figure:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
• Figure 1 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
• Figure 2 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, 2002-2007 ($ MILLIONS)
• Figure 3 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, 2002-2007 ($ MILLIONS)
• Figure 4 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, 2001-2007 ($ MILLIONS)
• Figure 5 DISTRIBUTION NANOBIOTECH COMPANIES BY TECHNOLOGY CATEGORY (%)